Descartes-25 in Relapsed/Refractory Multiple Myeloma
Key facts
- Who runs it
- Cartesian Therapeutics
- Where
- Bethesda and Shreveport, United StatesSee the 2 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 9 people enrolled
- Started
- 25 Nov 2021
- Ended
- 8 Nov 2024
- Type of study
- Interventional, 4 groups
- Treatments tested
- Descartes-25
- Record updated
- 12 November 2024
- Why it stopped
- Phase 1 enrollment completed. Further clinical development terminated.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- 18 years and older'
- diagnosed with active R/RMM, who have failed 2 lines of treatment
- have measurable disease
Who cannot take part
- Patients with active plasma cell leukemia
Where in United States
Also in 1 other country, 1 site
- Center for Cancer and Blood DisordersBethesda, United States
- Louisiana State University Health Science Center at ShreveportShreveport, United States
About the trial
What the trial wants to find out
This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple Myeloma.
The 4 groups in the trial
- Arm 1: Dose Level 1Treatment being tested
Minimum of 3 patients per Dose Level will be treated sequentially with once weekly infusions for 3 weeks in a 28-day cycle until the Maximum Tolerated Dose (MTD) is reached.
Treatment: Descartes-25
- Arm 2: Dose Level 2Treatment being tested
Minimum of 3 patients per Dose Level will be treated sequentially with once weekly infusions for 3 weeks in a 28-day cycle until the Maximum Tolerated Dose (MTD) is reached.
Treatment: Descartes-25
- Arm 3: Dose Level 3Treatment being tested
Minimum of 3 patients per Dose Level will be treated sequentially with once weekly infusions for 3 weeks in a 28-day cycle until the Maximum Tolerated Dose (MTD) is reached.
Treatment: Descartes-25
- Arm 4: Dose ExpansionTreatment being tested
In Arm 2, the MTD established in Arm 1 will be administered for 3 28-day cycles to further evaluate the product's safety and preliminary efficacy.
Treatment: Descartes-25
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase I/IIa Study of Descartes-25 in Patients With Relapsed/Refractory Multiple Myeloma
- Record updated
- 12 November 2024